posted on 2017-06-28, 00:00authored byChristof Regl, Therese Wohlschlager, Johann Holzmann, Christian G. Huber
Oxidation
of biopharmaceuticals may affect their bioactivity, serum
half-life, and (bio)chemical stability. The Fc domain of IgG monoclonal
antibodies (mAbs) contains two methionine residues which are susceptible
to oxidation. Here, we present a middle-down approach employing the
cysteine protease IdeS under reducing conditions to obtain three mAb
subunits of approximately 25 kDa: Fc/2, Fd′, and LC. These
subunits were separated by ion-pair reversed-phase high-performance
liquid chromatography (IP-RP-HPLC) and detected by UV spectroscopy
as well as Orbitrap mass spectrometry (MS), as well as MS upon all-ion
fragmentation (AIF-MS). We evaluated the feasibility of three strategies
for absolute quantification of oxidation in the Fc region of hydrogen
peroxide-stressed Rituximab, using a single, commercially available
software platform both for data acquisition and evaluation: UV spectroscopy,
full-scan MS, and monitoring of product ions obtained by AIF-MS. UV
spectroscopy showed the lowest limits of quantification (LOQ) (0.96
ng μL–1) and featured the lowest relative
process standard deviation (Vx0%) of 7.2%
compared to MS and AIF-MS with LOQs of 1.24–4.32 ng μL–1 and relative process standard deviations of 9.0–14%,
respectively. Our approach is generic in that it allows monitoring
and quantification of oxidation in the Fc regions of fully human and
humanized IgG1 mAbs as well as of Fc-fusion proteins. This is exemplified
by limits of detection of 1.2%, 1.0%, and 1.2% of oxidation in drug
products containing the biopharmaceuticals Rituximab, Adalimumab,
and Etanercept, respectively. The presented method is an attractive
alternative to conventional time-intensive peptide mapping which is
prone to artificial oxidation due to extensive sample preparation.